Compound Planning Inc. Sells 24,013 Shares of Astrazeneca Plc $AZN

Compound Planning Inc. lessened its holdings in Astrazeneca Plc (NYSE:AZN) by 56.4% in the 1st quarter, Holdings Channel reports. The firm owned 18,570 shares of the company’s stock after selling 24,013 shares during the quarter. Compound Planning Inc.’s holdings in Astrazeneca were worth $3,662,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of AZN. Keebeck Wealth Management acquired a new stake in Astrazeneca in the 1st quarter worth approximately $237,000. Aureus Asset Management LLC bought a new position in shares of Astrazeneca in the first quarter valued at approximately $218,000. Clal Insurance Enterprises Holdings Ltd raised its position in shares of Astrazeneca by 51.8% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 258 shares of the company’s stock valued at $50,000 after purchasing an additional 88 shares during the period. Temasek Holdings Private Ltd acquired a new stake in shares of Astrazeneca in the first quarter worth $70,887,000. Finally, Baader Bank Aktiengesellschaft bought a new stake in shares of Astrazeneca during the 1st quarter worth $920,000. 20.35% of the stock is currently owned by institutional investors.

Astrazeneca Stock Up 0.2%

Shares of NYSE:AZN opened at $168.68 on Friday. The company’s fifty day moving average is $180.55 and its 200-day moving average is $187.97. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. Astrazeneca Plc has a 52 week low of $142.98 and a 52 week high of $212.71. The company has a market capitalization of $261.61 billion, a PE ratio of 25.33, a P/E/G ratio of 1.37 and a beta of 0.24.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.06. The firm had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Equities research analysts predict that Astrazeneca Plc will post 10.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

AZN has been the subject of a number of research analyst reports. Bank of America reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday, July 1st. HSBC cut shares of Astrazeneca from a “buy” rating to a “hold” rating in a research note on Monday, July 13th. Barclays reissued a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. Finally, Weiss Ratings downgraded Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 18th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $211.00.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.